28th May 2020 15:32
(Alliance News) - Oncimmune Holdings PLC on Thursday said it had signed a further contract with Roche Holding AG to profile autoantibodies in samples collected from patients during cancer immunotherapy trials.
Shares in Oncimmune were up 5.7% at 102.00 pence in London in afternoon trading.
Immunodiagnostics firm Oncimmune recently completed its two-month foothill project with Roche and the new project will look at baseline and on-treatment autoantibody profiles as biomarkers in patients who received cancer immunotherapy. Oncimmune's SeroTag biomarker discovery platform will be used to do this.
An autoantibody is a type of antibody made by the immune system that attacks a person's own proteins. In this the case of immunotherapy, the goal is to encourage the immune system to attack cancer cells.
"This new contract provides Oncimmune with the opportunity to further contribute to the understanding of individual patient responses to immunotherapy through immune profiling," the company said.
Financial details were not disclosed, although Oncimmune said the contract "has a substantial upfront element" and will begin straight away, with initial results due within three months and the project to complete by November.
Oncimmune Chief Executive Adam Hill said: "This significant contract with Roche not only builds upon the excellent collaborative work between the Oncimmune and Roche teams in recent months, but it strikes to the heart of understanding as to why cancer patients have differing responses to the same immunotherapy.
"Since acquiring Oncimmune Germany last year, we have grown the pipeline of potential commercial projects with major pharmaceutical and biotechnology companies, and this contract, the largest we have signed to date, provides further evidence of our ability to convert pipeline opportunities into contracted revenues."
By Anna Farley; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Oncimmune